Viatris Puts OTC Business Up For Sale
Viatris has decided to exit the consumer health market and has put up for sale an OTC business which is thought to generate around $1.0bn in annual sales.
You may also be interested in...
UK Cialis Rx-To-OTC Switch World-First For Sanofi, H2 2023 Launch Planned
The UK is the first country to allow OTC access to Sanofi's tadalafil-based erectile dysfunction drug Cialis following a successful switch. Approved as a pharmacy medicine, Sanofi will launch Cialis Together in the second half of the year. Cialis will compete against Viatris' sildenafil-based Viagra Connect in the men's sexual health and wellness category, which has seen a proliferation of products in recent months.
People On The Move: Appointments At Viatris, HFMA, Biofarma
A round up of the latest appointments in the health and wellness sector: Viatris names Scott Smith CEO as it prepares to exit OTC; the UK's Health Food Manufacturers' Association plans leadership change; Italy's Biofarma hires ex-Almirall CEO to lead company.
Defend-Eeze Launches In US Zinc Cold Remedy Market
Vespyr, incorporated in December 2021 after operating as Nurya when it acquired Cold-Eeze from Mylan in May that year, offers Defend-Eeze in lozenges containing echinacea, elderberry and vitamins C and D3 in addition to zinc.